Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BTG Gains First U.S. Approval With Methotrexate Antidote Voraxaze

This article was originally published in The Pink Sheet Daily

Executive Summary

Transatlantic specialty pharma BTG adds to its antidote portfolio with FDA approval of Voraxaze, an enzyme drug that breaks down methotrexate in patients whose kidneys are failing due to high serum levels of the chemotherapeutic. BTG also markets snake-bite therapy CroFab and DigiFab for digitalis overdose and recently licensed a late-stage drug to counter toxicity from 5-FU chemotherapy.

Advertisement

Related Content

BTG Makes Two Buys To Build Interventional Medicine Business
FDA Wants To Help You Develop Drugs
Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
CDER Approvals In January Came Early And Often
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
NME Candidates For 2012 Have Modest Ambitions; Standard Reviews And Small Molecules Dominate
With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus
Specialty Pharma In Europe: Is Long-Term Independence Still An Option?
No AstraZeneca Cash Takeover; BTG Offers Protherics Stock Deal Instead

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073267

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel